Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6710-6721

  Shimizu, Masahito ^a   Suzui, Masumi ^a,c   Deguchi, Atsuko ^a   Lim, Jin T E ^a   Xiao, Danhua ^a   Hayes, Julia H ^b   Papadopoulos, Kyriakos P ^b   Weinstein, I Bernard ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b University of the Ryukyus ^*  (United States)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC RETINOID; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 8; CASPASE 9; CHLORAMPHENICOL ACETYLTRANSFERASE; CYCLIN D1; MESSENGER RNA; NIK 333; OSI 461; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR BETA; RETINOID DERIVATIVE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CYCLIC GMP; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; LIVER NEOPLASMS; MICROFILAMENT PROTEINS; MODELS, BIOLOGICAL; PHOSPHOPROTEINS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECEPTORS, RETINOIC ACID; RECOMBINANT FUSION PROTEINS; RESPONSE ELEMENTS; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULINDAC; TRANS-ACTIVATORS; TRANSFECTION; TRETINOIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 5144223225     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0659     Document Type: Article

References (56)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
2. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92.
3. Koda M, Murawaki Y, Mitsuda A, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer (Phila) 2000;88:529-37.
4. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991;5:2924-33.
5. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
6. Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst (Bethesda) 1984;73:1389-93.
7. Nakamura N, Shidoji Y, Yamada Y, et al. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995;207:382-8.
8. Yasuda I, Shiratori Y, Adachi S, et al. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002;36:660-71.
9. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561-7.
10. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-7.
11. Suzui M, Masuda M, Lim JT, et al. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002; 62:3997-4006.
12. Obora A, Shiratori Y, Okuno M, et al. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002;36:1115-24.
13. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54.
14. Garcia AD, Ostapchuk P, Hearing P. Functional interaction of nuclear factors EF-C, HNF-4, and RXR alpha with hepatitis B virus enhancer I. J Virol 1993;67:3940-50.
15. Matsushima-Nishiwaki R, Okuno M, Adachi S, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61: 7675-82.
16. Matsushima-Nishiwaki R, Shidoji Y, Nishiwaki S, et al. Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol Cell Endocrinol 1996;121:179-90.
17. Benbrook D, Lernhardt E, Pfahl M. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature (Lond) 1988;333: 669-72.
18. de The H, Marchio A, Tiollais P, Dejean A. A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature (Lond) 1987;330:667-70.
19. Sever CE, Locker J. Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol Carcinog 1991;4:138-44.
20. Wan YJ, Wang L, Wu TC. Expression of retinoic acid receptor genes in developing rat livers and hepatoma cells. Lab Investig 1992; 66:646-51.
21. Sun SY, Wan H, Yue P, Hong WK, Lotan R. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 2000;275:17149-53.
22. Seewaldt V, Johnson B, Parker M, Collins S, Swisshelm K. Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ 1995;6:1077-88.
23. Hayashi K, Yokozaki H, Naka K, et al. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn J Cancer Res 2001;92:42-50.
24. de The H, Marchio A, Tiollais P, Dejean A. Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes. EMBO J 1989;8:429-33.
25. Yamada Y, Shidoji Y, Fukutomi Y, et al. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994;10:151-8.
26. Shimizu M, Suzui M, Deguchi A, Lim JT, Weinstein IB. Effects of acyclic retinoid on growth, cell cycle control, EGFR signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res 2004;10:1130-40.
27. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-42.
28. Soh JW, Mao Y, Kim MG, et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 2000;6:4136-41.
29. Li H, Liu L, David ML, et al. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 2002;64:1325-36.
30. Moon EY, Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 2002;62:5711-9.
31. Ferrara FF, Fazi F, Bianchini A, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001;61:2-7.
32. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149-55.
33. Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25- Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 2000;60:2040-8.
34. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001;7:4220-9.
35. Soriano AF, Helfrich B, Chan DC, et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999;59:6178-84.
36. Shirin H, Pinto JT, Kawabata Y, et al. Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide. Cancer Res 2001;61:725-31.
37. Deguchi A, Soh JW, Li H, et al. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther 2002;1:803-9.
38. Soh JW, Lee EH, Prywes R, Weinstein IB. Novel roles of specific isoforms of protein kinase C in activation of the c-fos serum response element. Mol Cell Biol 1999;19:1313-24.
39. Albanese C, Johnson J, Watanabe G, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-97.
40. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
41. Cho Y, Talmage DA. Protein kinase Calpha expression confers retinoic acid sensitivity on MDA-MB-231 human breast cancer cells. Exp Cell Res 2001;269:97-108.
42. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-7.
43. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000;21:857-64.
44. Taya Y. RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci 1997;22:14-7.
45. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
46. Harper JW, Elledge SJ, Keyomarsi K, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995;6:387-400.
47. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
48. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 1996; 271:31723-8.
49. de The H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature (Lond) 1990;343:177-80.
50. Snowden AW, Anderson LA, Webster GA, Perkins ND. A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation. Mol Cell Biol 2000;20:2676-86.
51. Teraishi F, Kadowaki Y, Tango Y, et al. Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment. Int J Cancer 2003;103:833-9.
52. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Investig 1997; 99:403-13.
53. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
54. Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033-45.
55. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
56. Sun SY, Yue P, Hong WK, Lotan R. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 2000;60:6537-43.